Abstract 383P
Background
Pancreatic cancer is a highly malignant tumor with a poor prognosis and 5-year survival rate is less than 10%. Surgical resection is the only possible effective means for radical cure of pancreatic cancer. However, the overall survival after radical operation increased from 18 to 26 months while the overall 5-year survival rate was only 5-20%. Therefore, how to stratify patients and predict the prognosis is the important problems to solve in pancreatic cure. We try to obtain the molecular prognosis marker for resectable pancreatic cancer by genes mutation analysis in this study.
Methods
In this study, paired bloods and tissues were collected for investigating the gene variations among 17 patients with pancreatic ductal adenocarcinoma. We selected a panel of 143 clinically relevant cancer genes for targeted sequencing of the whole exons. Freebayes software was used for mutation calling of the samples, and Pearson correlation coefficient was used for gene variations associations between bloods and tissues. The Kaplan-Meier survival analysis was performed for OS and PFS in all patients.
Results
A total of 11,918 gene variations was shared by both the tissues and bloods. The gene mutation frequency was consistent between tissues and bloods with Pearson correlation coefficient of 0.99. We selected 62 genes in tissues and 35 genes in bloods annotated with the pathogenesis relevant gene variation for further analysis. In total, 35 of 62 genes identified in tissues were detected in bloods where 85 of 120 gene variations in bloods were found in tissues. KRAS, TP53, BRCA2, PTPN11 and TSC2 were the most common mutated genes detected in the tissues, and BRCA2, BRCA1, TERT, TP53 were the most common mutated genes in bloods. The Kaplan-Meier survival analysis found that ATM-BRCA1 and BRCA2 mutation had a poorer prognosis.
Conclusions
In the study, mutations in 143 cancer related genes of paired bloods and tissues in 17 patients were detected and three mutation genes could be the diagnostic biomarker for verification in the future. We also revealed the consistency of gene mutations between the tissues and bloods to some extent. Our results provide the reference for cancer detection and treatment for resectable pancreatic cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Geneis Co. Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract